4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives
暂无分享,去创建一个
K. Varani | F. Vincenzi | D. Dal Ben | R. Volpini | F. Melani | Silvia Pasquini | N. Mennini | Giulia Nerli | D. Catarzi | V. Colotta | F. Varano | Erica Vigiani | Sara Calenda
[1] R. Hay,et al. Putting the burden of skin diseases on the global map , 2021, The British journal of dermatology.
[2] M. Hardman,et al. Wound healing: cellular mechanisms and pathological outcomes , 2020, Open Biology.
[3] K. Varani,et al. Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists , 2019, Pharmaceuticals.
[4] S. Mishra,et al. Retention of strong intramolecular hydrogen bonds in high polarity solvents in binaphthalene–benzamide derivatives: extensive NMR studies , 2019, RSC advances.
[5] G. Marucci,et al. Non-Nucleoside Agonists of the Adenosine Receptors: An Overview , 2019, Pharmaceuticals.
[6] K. Varani,et al. Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity. , 2019, Journal of medicinal chemistry.
[7] E. D. du Toit,et al. Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells , 2019, Purinergic Signalling.
[8] W. Baumeister,et al. Structure of the adenosine-bound human adenosine A1 receptor–Gi complex , 2018, Nature.
[9] K. Varani,et al. The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor. , 2018, European journal of medicinal chemistry.
[10] Nicole Diedrichs,et al. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases , 2017, ChemMedChem.
[11] K. Varani,et al. Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis , 2017, International journal of molecular sciences.
[12] G. Marucci,et al. Simulation and Comparative Analysis of Different Binding Modes of Non‐nucleoside Agonists at the A2A Adenosine Receptor , 2016, Molecular informatics.
[13] K. Varani,et al. Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? , 2016, Trends in pharmacological sciences.
[14] P. Maiti,et al. First report of multiple metal ions containing glass–ceramic material as a heterogeneous ditopic catalyst for the chromatography free synthesis of 2-amino-3,5-dicarbonitrile-6-arylthio-pyridines in water , 2015 .
[15] Douglas E. V. Pires,et al. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.
[16] David Rodríguez,et al. Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor , 2015, J. Chem. Inf. Model..
[17] K. Varani,et al. TRR469, a potent A1 adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice , 2014, Neuropharmacology.
[18] B. Cronstein,et al. Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist , 2013, British journal of pharmacology.
[19] C. Langmead,et al. Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy , 2013, Molecular Pharmacology.
[20] J Bajgar,et al. Transdermal drug delivery in vitro using diffusion cells. , 2012, Current medicinal chemistry.
[21] R. Stevens,et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.
[22] Kenneth A Jacobson,et al. Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.
[23] B. Fredholm,et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.
[24] C. Kunick,et al. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. , 2010, European journal of medicinal chemistry.
[25] K. Varani,et al. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. , 2009, Arthritis and rheumatism.
[26] M. Sridhar,et al. Novel ZnCl 2-catalyzed one-pot multicomponent synthesis of 2-amino-3,5-dicarbonitrile-6-thio-pyridines , 2009 .
[27] B. Cronstein,et al. Adenosine receptor agonists for promotion of dermal wound healing. , 2009, Biochemical pharmacology.
[28] Hui Lu,et al. A single-molecule perspective on the role of solvent hydrogen bonds in protein folding and chemical reactions. , 2008, Chemphyschem : a European journal of chemical physics and physical chemistry.
[29] P. Pacher,et al. A2A receptors in inflammation and injury: lessons learned from transgenic animals , 2008, Journal of leukocyte biology.
[30] A. Kornienko,et al. One-step synthesis of heterocyclic privileged medicinal scaffolds by a multicomponent reaction of malononitrile with aldehydes and thiols. , 2007, The Journal of organic chemistry.
[31] F. Attaby,et al. Synthesis, Reactions, and Antiviral Activity of 6′-Amino-2′-thioxo-1′,2′-dihydro-3,4′-bipyridine-3′,5′-dicarbonitrile , 2007 .
[32] A. IJzerman,et al. ZM241385, DPCPX, MRS1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A2B Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.
[33] A. Kornienko,et al. One-step, three-component synthesis of pyridines and 1,4-dihydropyridines with manifold medicinal utility. , 2006, Organic letters.
[34] A. IJzerman,et al. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. , 2005, Journal of medicinal chemistry.
[35] A. IJzerman,et al. New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.
[36] W. Bachovchin,et al. Review: Contributions of NMR spectroscopy to the study of hydrogen bonds in serine protease active sites , 2001 .
[37] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[38] R. Paes-de-Carvalho,et al. Long-term activation of adenosine A2a receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons , 2001, Brain Research.
[39] R. Cunha,et al. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors , 2001, Neurochemistry International.
[40] J. Ribeiro,et al. Fine-tuning neuromodulation by adenosine. , 2000, Trends in pharmacological sciences.
[41] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[42] J. Dobson,et al. Adenosine A2a receptors increase arterial endothelial cell nitric oxide. , 1998, The Journal of surgical research.
[43] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[44] W. Buurman,et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. , 1994, Journal of immunology.
[45] Mark S. Gordon,et al. General atomic and molecular electronic structure system , 1993, J. Comput. Chem..
[46] B. Cronstein,et al. Adenosine receptors in wound healing, fibrosis and angiogenesis. , 2009, Handbook of experimental pharmacology.
[47] Mark S. Gordon,et al. Chapter 41 – Advances in electronic structure theory: GAMESS a decade later , 2005 .
[48] Kwang S. Kim,et al. Theory and applications of computational chemistry : the first forty years , 2005 .
[49] A. de Mendonça,et al. Adenosine and synaptic plasticity , 2001 .
[50] K. Klotz,et al. [3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. , 2000 .